hapabapa My last article about Amazon.com, Inc. (NASDAQ:AMZN) was published in December 2023 and not only was I wrong about Amazon in my last article – I was also too cautious in my previous articles. Amazon reached its previous all-time high again – a scenario I saw as rather unlikely in my previous articles. When…
Richard Darko/iStock via Getty Images Introduction Many may be wondering how well BDCs will fare in 2024, with rates still expected to decline. I am a big believer in the sector and think they are more than just high interest rate environment investments. With the banking crisis roughly a year ago causing tighter lending standards,…
igoriss A little over a year ago, in the middle of February of 2023, I found myself analyzing Gates Industrial Corp (NYSE:GTES). For those not aware of the company, it operates as a producer and seller of engineered power transmission and fluid power solutions. Most of the company’s products are sold on the aftermarket, but…
Rich Fury Introduction In my previous articles (article 1) (article 2), I had a sell rating on SoFi Technologies (NASDAQ:SOFI). In both of the articles, my primary argument for a sell thesis was the potential macroeconomic headwind. At the time, I believed that the slowly declining consumers’ financial health could create a headwind for the…
Klaus Vedfelt We previously covered SoFi Technologies (NASDAQ:SOFI) in November 2023, discussing the impressive results across all of its segments, further aided by the returning student loan refinancing as the US federal student loan repayment restarted from October 2023. Combined with the growing bank deposits, the contribution to its lower cost funding, and the promising…
Sundry Photography In our previous analysis of Lam Research Corporation (NASDAQ:LRCX), we assessed the company amid geopolitical tensions with the US government imposing export restrictions on semicon equipment to China. Still, we estimated a minimal impact to the company of up to only 2.2% of revenues on both memory and logic equipment restrictions, thus affirming…
William_Potter Introduction Last time I wrote on FS KKR Capital (NYSE:FSK) was back in August in an article titled, “The Road Ahead Looks Promising.” That was right before the BDC reported its Q2 earnings. Some time has passed since reporting Q3 earnings. So, I felt like it was time to take another look at them….
NoSystem images A couple of months ago, I was surprised by the large drop in Rivian Automotive, Inc. (NASDAQ:RIVN) shares after a convertible debt offering. While I had been telling everyone that another capital raise was eventually coming, the sooner-than-expected debt deal had investors a bit worried. Since then, Rivian shares have rallied more than…
Love Employee/iStock via Getty Images Topline Summary Aadi Bioscience (NASDAQ:AADI) is a microcap developmental biotech placing its bets on a single agent, a nanoliposomal encapsulation of the mTOR inhibitor sirolimus. They have one approved indication, with several others being explored in clinical trials. Their tissue-agnostic trial could end up being a massive win for the…
Natee127 Elevator Pitch I rate Jiayin Group Inc. (NASDAQ:JFIN) shares as a Hold. The company’s financial prospects relating to loan facilitation and margins are weak. But JFIN stock is trading at depressed valuations, and the company has done well in the area of shareholder capital return. Company Overview In its press releases, Jiayin Group describes…
AUNG MYO HTWE/iStock via Getty Images Investment Overview: Zentalis Believes ‘Pipeline-In-A-Pill” Azenosertib Will Soon Make Grade In Ovarian Cancer Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) is a clinical-stage biotech headquartered in New York that was listed on the Nasdaq in April 2020, raising ~$165m via the issuance of ~9.2m shares priced at $18 per share. At the…
YvanDube I’ve had my eye on Costco Wholesale Corporation (NASDAQ:COST) for a long time now. This is my first time covering the company on Seeking Alpha, and I initiate my coverage with a “HOLD” rating. Costco has always intrigued me because it consistently trades at high valuations. Right now, the stock is trading at a…
FatCamera Reason for the update: earnings and clinical catalysts This article is a revisit of Valneva (OTCPK:INRLF) (NASDAQ:VALN) with a) updated analysis on Q2 2023 results and b) upcoming catalysts (vaccine PDUFA) that we find material for the stock’s price action as we move into Q4 2023 and Q1 2024 in a few months. We…
Pgiam/iStock via Getty Images Investment briefing United Therapeutics Corporation (NASDAQ:NASDAQ:UTHR) pulled in with a strong set of quarterly results before the open yesterday. Following my May profiling of UTHR the company’s equity stock has caught a reasonable bid, and the latest set of numbers adds to an already impressive set of economic characteristics in my…